Imprimis Pharmaceuticals Story

Slightly above 67% of Imprimis Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Imprimis Pharmaceuticals suggests that many traders are alarmed regarding Imprimis Pharmaceuticals' prospects. Imprimis Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in Imprimis Pharmaceuticals. The current market sentiment, together with Imprimis Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Imprimis Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Imprimis Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Imprimis daily returns and investor perception about the current price of Imprimis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
  

Requested story not found. it has been either deleted or moved. View all stories for Imprimis Pharmaceuticals.

Imprimis Pharmaceuticals Latest Timeline

Imprimis Pharmaceuticals is listed for 0.00. About 23.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.3. Imprimis Pharmaceuticals had not issued any dividends in recent years. The entity had 1:5 split on the 8th of February 2013.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in Imprimis Stock

If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine